Company Filing History:
Years Active: 2013
Title: Fabien Schmidlin: Innovator in Selective Inhibitors
Introduction
Fabien Schmidlin is an inventor known for his contributions to the field of medicinal chemistry. His work focuses on developing innovative compounds that can address various metabolic and psychological disorders. Schmidlin's research has the potential to impact the treatment of conditions such as diabetes, obesity, and anxiety.
Latest Patents
Schmidlin holds a patent titled "Fused Pyrrolidino-Cyclopropane Derivatives As Selective 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors." This invention relates to fused pyrrolidino-cyclopropane derivatives that act as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11-β-HSD-1). The compounds developed through this research are aimed at treating and preventing metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension, and other related diseases.
Career Highlights
Throughout his career, Schmidlin has focused on the synthesis and application of novel chemical compounds. His work has contributed to a deeper understanding of how specific inhibitors can be utilized in therapeutic settings. Despite having a current count of 1 patents, his research continues to pave the way for future innovations in the field.
Collaborations
Schmidlin has collaborated with notable researchers, including Eric Valeur and Franck Lepifre. These partnerships have enhanced the scope and impact of his research, allowing for a multidisciplinary approach to tackling complex health issues.
Conclusion
Fabien Schmidlin is a promising inventor whose work in selective inhibitors holds significant potential for advancing medical treatments. His innovative approach to addressing metabolic and psychological disorders showcases the importance of research in developing effective therapies.